Meet Positives banner728x90

Rational Vaccine Inc

If you are like many HSV1 and HSV2 sufferers, a cure or even honest talk of a cure are long overdue.   Herpes or genital herpes symptoms are horrible, not the physical ones but the emotional symptoms leave most victims feeling low, lonely and even dirty.  HSV is a silent epidemic impacting new victims every year.  Just recently the WHO (World Health Organization) released an article stating that as much as 2/3 of the world’s population is HSV positives and with the recent trend of “hook-ups” millennials are expected to skyrocket the ever growing epidemic.

So what can a sexually active person do to protect themselves from HSV?  Unfortunately condoms are no guarantee but they will help protect you from HIV and that in itself is well worth the little extra effort.

Fortunately for HSV victims Rational Vaccine has possibly cracked the HSV vaccine mystery, though it is not a cure, there is good idea that one is coming soon.

Here is more information about Rational Vaccine Inc which first appeared on  liveherpesvaccine.com  in it’s article  Herpes Vaccine Research 

March 12, 2016

I apologize to blog followers for the relative radio silence.   In the next two weeks, I hope to put up a few posts to update blog followers on where my attention has been focused the past year.  Many people have asked “How can I help?” or have offered to launch their own efforts for “crowd funding” of my HSV-2 vaccine research.  I have chosen a different path to monetize the path forward for a HSV-2 vaccine and those plans involve selling new products to meet the underserved needs of patients who are daily impacted by HSV-1 and HSV-2.

I have joined forces with some business-minded individuals to form Rational Vaccines (RVx), Inc. in April 2015, and we raised about three-quarters of a million dollars last year for the purpose of starting an initially herpes-focused company.  RVx’s goal is to start offering real solutions to herpes sufferers today.  Our products will serve the needs of tens of millions of people who suffer with HSV-1 and HSV-2 herpetic diseases, and the many complications of potential exposures that require diagnostic testing.  While genital herpes will be a major focus, RVx’s ultimate goal is to prevent all forms of herpetic disease including oral herpes, herpes-induced neuralgia, ocular herpes, neonatal herpes, and herpes encephalitis.

RVx anticipates that our company’s website will be live by Summer 2016.  In the interim, the most concrete thing blog followers and their contacts can do, today, to show support for RVx’s efforts is offer our investors a better idea of the scope of the hidden demand for our products.  If you would personally consider purchasing one or more of the products described below, then please sign up for the relevant waiting list below.  Sending an email does not obligate you to a later purchase, and likewise does not obligate you to participate in a clinical trial.

It would greatly help if, in those emails, you would use your real name, phone number, and a real email address where you can be reached when RVx is ready to launch the product line or clinical trial that is relevant to your inquiry.   If you can spare the time, a brief paragraph explaining your medical needs would help us better respond once our website is live.

I briefly summarize the three immediate product lines below, and I will follow this week with a post on each that outlines why I believe each stands head-and-shoulders above anything else that is being offered or discussed in the space of herpes vaccines or diagnostics.  Finally…….  real solutions for real-world problems that have gone unaddressed for too long.

Sincerely yours,

Bill Halford

Herpes victims may have to wait until there is a cure or until this vaccine is FDA cleared, until then, keep the conversation going by joining Meet Positives Herpes Support 

=====================================

The HSV-Type-Specific ABVIC Test:   rvx.abvic.test@gmail.com

Sample HSV Type-Specific ABVIC-2

Image Credit: LiveHerpesVaccine.com

https://liveherpesvaccine.com/2016/03/12/hsv-type-specific-abvic/

  1.  The HSV-Type-Specific ABVIC Test represents a 100-fold better way to test for antibodies to herpes simplex virus 1 (HSV-1) versus HSV-2.  The current standard  of care for herpes antibody testing is the HerpeSelect Test, and this test yields a 4% HSV-2 false-positive rate. That is, 4 out of every 100 people who order the HSV-2 HerpeSelect test are told they may have HSV-2, but the test results are equivoval.  In side-by-side tests with RVx’s new ABVIC test (manuscript in preparation), the HSV-Type-Specific ABVIC Test resolves >90% of these false-positive HSV-2 results.   If you or someone you know has been walking under the cloud of believing they have HSV-2 just because “a doctor-ordered test said so,” please consider ordering the HSV-Type-Specific ABVIC Test from RVx when you website goes live in Summer 2015.  In the meantime, if you with to sign up for ABVIC testing ($250 per test), then please email the following sign-up address:  rvx.abvic.test@gmail.com.  It is anticipated that RVx will be able to make this product generally available to the public by July 2015.

===================================

Theravax‾² vaccine trials:   rvx.therapeutic.vaccine@gmail.com

https://liveherpesvaccine.com/2016/03/12/rvx-therapeutic-hsv-2-vaccine/

2.  Theravax‾² vaccine.  RVx is planning clinical trials of our live-attenuated therapeutic HSV-2 vaccine, which the published literature indicates is about 40 – 100 times more effective than any of HSV-2 subunit type vaccines developed over the past 30 years.  If you have lived with an uncontrolled case of HSV-2 genital herpes for more than 3 years that causes more than 6 outbreaks, causes constant nerve pain, or does not respond to conventional antiviral drugs, then please consider emailing to the following sign-up address for future trials of the Theravax‾² vaccine:rvx.therapeutic.vaccine@gmail.com.   Because of the more complex regulatory guidelines surrouding vaccines, it is difficult to predict when this product would be broadly commercially available.  However, rest assured that RVx will be pursuing many paths to bring this incredibly safe and highly effective HSV-2 vaccine to market somewhere in the world as soon as possible.

================================

Profavax‾² vaccine trials:   rvx.prophylactic.vaccine@gmail.com

3.  Profavax‾² vaccine.  Immediately upon completing therapeutic HSV-2 vaccine trials, RVx is planning clinical trials of our live-attenuated HSV-2 vaccine as a prophylactic in individuals who are in discordant relationships.  The published literature indicates that the Profavax‾² vaccine should be about 40 – 100 times more effective than any of HSV-2 subunit type vaccines that have been failing in human clinical trials over the past 30 years.  If you want to give yourself the greatest opportunity to be protected against the risk of ever contracting HSV-2 genital herpes disease, then consider emailing to the following sign-up address for future trials of the Profavax‾² vaccine: rvx.prophylactic.vaccine@gmail.com.   Because of the more complex regulatory guidelines surrounding vaccines, it is difficult to predict when this product would be broadly commercially available.  However, rest assured that RVx will be pursuing many paths to bring this incredibly safe and highly effective HSV-2 vaccine to market somewhere in the world as soon as possible.

Rational Vaccine

Herpes victims may have to wait until there is a cure or until this vaccine is FDA cleared, until then, keep the conversation going by joining Meet Positives Herpes Support 

Add Comment